My ePortfolio Register   

SIOG 2017 /
Benefits and drawbacks of dexrazoxane

9th - 11th Nov 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.11.17
Views: 131
Rating:

Dr Robin Jones - The Institute of Cancer Research, London, UK

Dr Jones talks to ecancer at SIOG 2017 in Warsaw about cardiotoxicities involved with anthrocyclines.

Dr Jones focusses on dexrazoxane as it is the only clinically proven cardio-protective agent against these toxicities.

He discusses the concerns surrounding this drug, and whether he'd advise it's use alongside chemotherapy. 

This service has been kindly supported by an unrestricted grant from Janssen Oncology.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence